SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Business
venBio Closes $394 Million Life Sciences VC Fund
The capital was raised from existing and new investors, including a broad range of institutional investors comprised of pharmaceutical companies, corporate pensions, financial institutions, endowments and foundations, family offices and funds-of-funds.
April 8, 2020
 · 
4 min read
 · 
Gail Dutton
BioForest
Comparison: COVID-19 Innovations in the U.S. Versus the Rest of the World
The United States leads the world in biotech innovation, but does it also lead the world in the development of COVID-19 diagnostics, vaccines and therapeutics?
April 7, 2020
 · 
5 min read
 · 
Gail Dutton
BioCapital
Compare Update: 2003 SARS Pandemic Versus 2020 COVID-19 Pandemic
SARS was called the first pandemic of the 21st century. It would not be the last. Nor would it be the most deadly.
April 3, 2020
 · 
5 min read
 · 
Gail Dutton
Business
Pinpoint Therapeutics Targets COVID-19 With New Autophagy Pathway
Pinpoint Therapeutics believes that its approach to treat therapy-resistant cancers also may be effective against COVID-19.
April 2, 2020
 · 
4 min read
 · 
Gail Dutton
Business
VCs Tell Biotechs: Hunker Down, Manage Your Cash Carefully
“Companies active in the fight against COVID-19 will have plenty of funding, and those targeting severe unmet needs will weather the storm better than others. But, for the rest, it will be rough for the next 12 months,” said Otello Stampacchia, founder of Omega Funds.
April 1, 2020
 · 
3 min read
 · 
Gail Dutton
Business
GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy
First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.
March 30, 2020
 · 
4 min read
 · 
Gail Dutton
BioForest
Work and Hiring Slowing in Biotech, But Layoffs Unlikely
The COVID-19 pandemic isn’t likely to end soon. Instead, the crisis stage may continue for weeks or even months before business regains some semblance of normality. The good news is that while biotech companies have slowed their hiring initiatives, layoffs remain unlikely at this point. Instead, biotech companies are enhancing flexibility on nearly every front.
March 27, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Biotech Calls for More Collaboration and Communication During COVID-19 Pandemic
One of the key takeaways from BIO-Europe Spring 2020 was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
March 27, 2020
 · 
4 min read
 · 
Gail Dutton
Some Drugs Being Rationed as Suppliers Continue to See Increased Orders
Lab suppliers report sales and backorders are up, and some distributors are allocating medications. For most biotech companies, supplies are available, although they are monitoring the situation closely.
March 26, 2020
 · 
4 min read
 · 
Gail Dutton
Business
How Life Sciences Labs and Companies Prepped for Mandatory Stay-at-Home Orders
Organizations should plan for the worst and hope for the best, ensuring critical research can be continued without risking the safety of employees or the continuity of the company.
March 24, 2020
 · 
3 min read
 · 
Gail Dutton
Business
EU Pharma Strategy Targets Competition and the Environment
Europe’s new pharmaceutical roadmap is designed to reinvigorate innovation in the pharmaceutical industry to make it competitive with the United States.
March 23, 2020
 · 
4 min read
 · 
Gail Dutton
Policy
BARDA: Athersys’ Cell Therapy “Highly Relevant” for COVID-19
“What we have could be a very powerful weapon against these types of viral outbreaks or pandemics because it isn’t pathogen- or virus-specific and could be broadly relevant in these types of situations,” Gil Van Bokkelen, Ph.D., Athersys CEO, told BioSpace.
March 20, 2020
 · 
4 min read
 · 
Gail Dutton
Policy
FDA Provides Welcome Guidance for Clinical Trials During COVID-19
The FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic, released Wednesday, are “a really good first step in ensuring that clinical trials continue with minimum disruption,” according to Jim Kremidas, executive director of the Association of Clinical Research Professionals (ACRP).
March 19, 2020
 · 
4 min read
 · 
Gail Dutton
Laboratory work at a blank steril bank. Cell splitting work.
Business
COVID-19’s Impact on Life Sciences Researchers
Work in the age of COVID-19 is in flux. Restrictions change daily, and life sciences researchers are finding their work lives considerably different than they were a few short weeks ago.
March 17, 2020
 · 
4 min read
 · 
Gail Dutton
Bio NC
Nimble Supply Chains Minimize Disruption
Even when manufacturing facilities are producing, widespread illness causes other delays.
March 16, 2020
 · 
4 min read
 · 
Gail Dutton
Load More